Model-Informed Precision Dosing of Antibiotics in Osteoarticular Infections

References

• Zimmerli W, Sendi P. Orthopaedic biofilm infections. APMIS. 2017;125(4):353–364. doi:10.1111/apm.12687
   PubMed Web of Science ®Google Scholar
• Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364(9431):369–379. doi:10.1016/S0140-6736(04)16727-5
   PubMed Web of Science ®Google Scholar
• Gupta A, Kowalski TJ, Osmon DR, et al. Long-term outcome of pyogenic vertebral osteomyelitis: a cohort study of 260 patients. Open Forum Infect Dis. 2014;1(3):ofu107. doi:10.1093/ofid/ofu107
   PubMedGoogle Scholar
• Pigrau C, Rodriguez-Pardo D, Fernandez-Hidalgo N, et al. Health care associated hematogenous pyogenic vertebral osteomyelitis: a severe and potentially preventable infectious disease. Medicine. 2015;94(3):e365. doi:10.1097/MD.0000000000000365
   Web of Science ®Google Scholar
• Uckay I, Holy D, Betz M, Sauer R, Huber T, Burkhard J. Osteoarticular infections: a specific program for older patients? Aging Clin Exp Res. 2021;33(3):703–710. doi:10.1007/s40520-019-01329-w
   Web of Science ®Google Scholar
• Walter N, Rupp M, Hinterberger T, Alt V. Prosthetic infections and the increasing importance of psychological comorbidities: an epidemiological analysis for Germany from 2009 through 2019. Orthopade. 2021. doi:10.1007/s00132-021-04088-7
   Web of Science ®Google Scholar
• Otto-Lambertz C, Yagdiran A, Wallscheid F, Eysel P, Jung N. Periprosthetic infection in joint replacement. Dtsch Arztebl Int. 2017;114(20):347–353. doi:10.3238/arztebl.2017.0347
   Web of Science ®Google Scholar
• Gundtoft PH, Pedersen AB, Varnum C, Overgaard S. Increased mortality after prosthetic joint infection in primary THA. Clin Orthop Relat Res. 2017;475(11):2623–2631. doi:10.1007/s11999-017-5289-6
   PubMed Web of Science ®Google Scholar
• Zmistowski B, Karam JA, Durinka JB, Casper DS, Parvizi J. Periprosthetic joint infection increases the risk of one-year mortality. J Bone Joint Surg Am. 2013;95(24):2177–2184.
   PubMed Web of Science ®Google Scholar
• Kremers HM, Nwojo ME, Ransom JE, Wood-Wentz CM, Melton LJ 3rd, Huddleston PM 3rd. Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009. J Bone Joint Surg Am. 2015;97(10):837–845. doi:10.2106/JBJS.N.01350
   PubMed Web of Science ®Google Scholar
• Yeo A, Ramachandran M. Acute haematogenous osteomyelitis in children. Br Med J. 2014;348:g66. doi:10.1136/bmj.g66
   Web of Science ®Google Scholar
• Lazzeri E, Bozzao A, Cataldo MA, et al. Joint EANM/ESNR and ESCMID-endorsed consensus document for the diagnosis of spine infection (spondylodiscitis) in adults. Eur J Nucl Med Mol Imaging. 2019;46(12):2464–2487. doi:10.1007/s00259-019-04393-6
   Web of Science ®Google Scholar
• Ondusko DS, Nolt D. Staphylococcus aureus. Pediatr Rev. 2018;39(6):287–298. doi:10.1542/pir.2017-0224
   PubMed Web of Science ®Google Scholar
• Nolla JM, Ariza J, Gómez-Vaquero C, et al. Spontaneous pyogenic vertebral osteomyelitis in nondrug users. Semin Arthritis Rheum. 2002;31(4):271–278. doi:10.1053/sarh.2002.29492
   Web of Science ®Google Scholar
• Perrotti PP, Corrales JL, Popescu BM. [Pyogenic vertebral osteomyelitis]. Medicina. 2009;69(5):513–518. [Spanish]
   Web of Science ®Google Scholar
• Titécat M, Senneville E, Wallet F, et al. Microbiologic profile of Staphylococci isolated from osteoarticular infections: evolution over ten years. Surg Infect (Larchmt). 2015;16(1):77–83. doi:10.1089/sur.2013.258
   PubMed Web of Science ®Google Scholar
• Sharff KA, Richards EP, Townes JM. Clinical management of septic arthritis. Curr Rheumatol Rep. 2013;15(6):332. doi:10.1007/s11926-013-0332-4
   PubMed Web of Science ®Google Scholar
• Tsantes AG, Papadopoulos DV, Vrioni G, et al. Spinal infections: an update. Microorganisms. 2020;8(4):476. doi:10.3390/microorganisms8040476
   PubMed Web of Science ®Google Scholar
• Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in Adults. Clin Infect Dis. 2015;61(6):e26–46. doi:10.1093/cid/civ482
   PubMed Web of Science ®Google Scholar
• Gelfand MS, Cleveland KO, Goswami RK, Heck R. Pathological fracture in acute osteomyelitis of long bones secondary to community-acquired methicillin-resistant Staphylococcus aureus: two cases and review of the literature. Am J Med Sci. 2006;332(6):357–360. doi:10.1097/00000441-200612000-00010
   Web of Science ®Google Scholar
• Kaandorp CJ, Krijnen P, Moens HJ, Habbema JD, van Schaardenburg D. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884–892. doi:10.1002/art.1780400516
   PubMed Web of Science ®Google Scholar
• Stepensky D, Kleinberg L, Hoffman A. Bone as an effect compartment: models for uptake and release of drugs. Clin Pharmacokinet. 2003;42(10):863–881. doi:10.2165/00003088-200342100-00001
   PubMed Web of Science ®Google Scholar
• Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;57(1):162–164. doi:10.1093/cid/cit189
   Web of Science ®Google Scholar
• Langeveld WT, Veldhuizen EJ, Burt SA. Synergy between essential oil components and antibiotics: a review. Crit Rev Microbiol. 2014;40(1):76–94. doi:10.3109/1040841X.2013.763219
   PubMed Web of Science ®Google Scholar
• Amorese V, Donadu M, Usai D, et al. In vitro activity of essential oils against Pseudomonas aeruginosa isolated from infected hip implants. J Infect Dev Ctries. 2018;12(11):996–1001. doi:10.3855/jidc.10988
   PubMed Web of Science ®Google Scholar
• Li J, Yang J, Wang Y. Applications of model-informed drug development (MIDD) on new drug research and development. Chin J Clin Pharmacol Ther. 2020;25(01):1-8. doi:10.12092/j.issn.1009-2501.2020.01.001
   Google Scholar
• Darwich AS, Polasek TM, Aronson JK, et al. Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy. Annu Rev Pharmacol Toxicol. 2021;61(1):225–245. doi:10.1146/annurev-pharmtox-033020-113257
   PubMed Web of Science ®Google Scholar
• Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: modelling and software. Clin Pharmacokinet. 2012;51(8):515–525. doi:10.1007/BF03261928
   Web of Science ®Google Scholar
• Ludden TM. Population pharmacokinetics. J Clin Pharmacol. 1988;28(12):1059–1063. doi:10.1002/j.1552-4604.1988.tb05714.x
   PubMed Web of Science ®Google Scholar
• Miller NA, Reddy MB, Heikkinen AT, Lukacova V, Parrott N. Physiologically based pharmacokinetic modelling for first-in-human predictions: an updated model building strategy illustrated with challenging industry case studies. Clin Pharmacokinet. 2019;58(6):727–746. doi:10.1007/s40262-019-00741-9
   PubMed Web of Science ®Google Scholar
• El-Khateeb E, Burkhill S, Murby S, Amirat H, Rostami-Hodjegan A, Ahmad A. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms. Biopharm Drug Dispos. 2021;42(4):107–117. doi:10.1002/bdd.2257
   PubMed Web of Science ®Google Scholar
• Ghathian K, Frimodt-Moller N. Beta-hemolytic streptococci A, C and G are susceptible to cloxacillin. APMIS. 2021;129(6):314–316. doi:10.1111/apm.13134
   Web of Science ®Google Scholar
• Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis. 2007;44(1):79–86. doi:10.1086/510079
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D1082. doi:10.1093/nar/gkx1037
   PubMed Web of Science ®Google Scholar
• Martinez-Taboada VM, Cabeza R, Cacho PM, Blanco R, Rodriguez-Valverde V. Cloxacillin-based therapy in severe septic bursitis: retrospective study of 82 cases. Joint Bone Spine. 2009;76(6):665–669. doi:10.1016/j.jbspin.2009.04.003
   Web of Science ®Google Scholar
• Courjon J, Garzaro M, Roger PM, et al. A population pharmacokinetic analysis of continuous infusion of cloxacillin during Staphylococcus aureus bone and joint infections. Antimicrob Agents Chemother. 2020;64(12). doi:10.1128/AAC.01562-20.
   Web of Science ®Google Scholar
• Gower PE, Dash CH. Cephalexin: human studies of absorption and excretion of a new cephalosporin antibiotic. Br J Pharmacol. 1969;37(3):738–747.
   Web of Science ®Google Scholar
• FDA Approved Drug Products: KEFLEX®(cephalexin) capsules. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050405s097lbl.pdf. Accessed December 31, 2021.
   Google Scholar
• Jalava S, Saarimaa H, Elfving R. Cephalexin levels in serum, synovial fluid and joint tissues after oral administration. Scand J Rheumatol. 1977;6(4):250–252. doi:10.3109/03009747709095460
   PubMed Web of Science ®Google Scholar
• Julie Autmizguine M, Watt KM, Théorêt Y, Kassir N, Laferrière C. Stefan parent bruce tapiéro and philippe ovetchkine. pharmacokinetics and pharmacodynamics of oral cephalexin in children with osteoarticular infections. Pediatr Infect Dis J. 2013;32(12):1340–1344. doi:10.1097/INF.0b013e3182a222a6
   Web of Science ®Google Scholar
• Gwee A, Autmizguine J, Curtis N, Duffull SB. Twice- and thrice-daily cephalexin dosing for staphylococcus aureus infections in children. Pediatr Infect Dis J. 2020;39(6):519–522. doi:10.1097/INF.0000000000002646
   Web of Science ®Google Scholar
• Spížek J, Řezanka T. Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance, and applications. Biochem Pharmacol. 2017;133:20–28. doi:10.1016/j.bcp.2016.12.001
   PubMed Web of Science ®Google Scholar
• Curis E, Pestre V, Jullien V, et al. Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. Infection. 2015;43(4):473–481. doi:10.1007/s15010-015-0773-y
   PubMed Web of Science ®Google Scholar
• Bouazza N, Pestre V, Jullien V, et al. Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. Br J Clin Pharmacol. 2012;74(6):971–977. doi:10.1111/j.1365-2125.2012.04292.x
   PubMed Web of Science ®Google Scholar
• Pietsch F, Bergman JM, Brandis G, et al. Ciprofloxacin selects for RNA polymerase mutations with pleiotropic antibiotic resistance effects. J Antimicrob Chemother. 2017;72(1):75–84. doi:10.1093/jac/dkw364
   PubMed Web of Science ®Google Scholar
• Varshney A, Ansari Y, Zaidi N, et al. Analysis of binding interaction between antibacterial ciprofloxacin and human serum albumin by spectroscopic techniques. Cell Biochem Biophys. 2014;70(1):93–101. doi:10.1007/s12013-014-9863-1
   Web of Science ®Google Scholar
• Sisto F, Bonomi A, Cavicchini L, et al. Human mesenchymal stromal cells can uptake and release ciprofloxacin, acquiring in vitro anti-bacterial activity. Cytotherapy. 2014;16(2):181–190. doi:10.1016/j.jcyt.2013.11.009
   Web of Science ®Google Scholar
• Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother. 2003;47(7):2283–2292. doi:10.1128/AAC.47.7.2283-2292.2003
   PubMed Web of Science ®Google Scholar
• Landersdorfer CB, Kinzig M, Hohl R, Kempf P, Nation RL, Sorgel F. Physiologically based population pharmacokinetic modeling approach for ciprofloxacin in bone of patients undergoing orthopedic surgery. ACS Pharmacol Transl Sci. 2020;3(3):444–454. doi:10.1021/acsptsci.0c00045
   PubMedGoogle Scholar
• Zahr N, Urien S, Aubry A, et al. Ciprofloxacin population pharmacokinetics during long-term treatment of osteoarticular infections. J Antimicrob Chemother. 2021;76(11):2906–2913. doi:10.1093/jac/dkab275
   Web of Science ®Google Scholar
• Norrby SR. Levofloxacin. Expert Opin Pharmacother. 1999;1(1):109–119. doi:10.1517/14656566.1.1.109
   PubMedGoogle Scholar
• FDA Approved Drug Products: levaquin (levofloxacin) oral tablets. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020634s071lbl.pdf. Accessed December 31, 2021.
   Google Scholar
• Rimmelé T, Boselli E, Breilh D, et al. Diffusion of levofloxacin into bone and synovial tissues. J Antimicrob Chemother. 2004;53(3):533–535. doi:10.1093/jac/dkh110
   PubMed Web of Science ®Google Scholar
• Marongiu G, Conte M, Verderosa V, et al. Late onset periprosthetic joint infection of the knee caused by Streptococcus anginosus. Case presentation and literature review. J Infect Dev Ctries. 2021;15(3):436–441. doi:10.3855/jidc.12326
   Web of Science ®Google Scholar
• Eloy G, Lebeaux D, Launay M, et al. Influence of renal function and age on the pharmacokinetics of levofloxacin in patients with bone and joint infections. Antibiotics. 2020;9(7). doi:10.3390/antibiotics9070401.
   Web of Science ®Google Scholar
• Cluzel RA, Lopitaux R, Sirot J, Rampon S. Rifampicin in the treatment of osteoarticular infections due to staphylococci. J Antimicrob Chemother. 1984;13(suppl_C):23–29. doi:10.1093/jac/13.suppl_C.23
   Web of Science ®Google Scholar
• Marsot A, Ménard A, Dupouey J, Muziotti C, Guilhaumou R, Blin O. Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. Br J Clin Pharmacol. 2017;83(5):1039–1047. doi:10.1111/bcp.13178
   Web of Science ®Google Scholar
• Marsot A, Ménard A, Dupouey J, Allanioux L, Blin O, Guilhaumou R. Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. Br J Clin Pharmacol. 2020;86(11):2319–2324. doi:10.1111/bcp.14319
   Web of Science ®Google Scholar
• Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51(5):1633–1642. doi:10.1128/AAC.01264-06
   PubMed Web of Science ®Google Scholar
• FDA Approved product label: DALVANCE(dalbavancin). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021883s007lbl.pdf. Accessed December 31, 2021.
   Google Scholar
• Veve MP, Patel N, Smith ZA, Yeager SD, Wright LR, Shorman MA. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive gram-positive infections. Int J Antimicrob Agents. 2020;56(6):106210. doi:10.1016/j.ijantimicag.2020.106210
   PubMed Web of Science ®Google Scholar
• Fiore V, De Vito A, Aloisio A, et al. Dalbavancin two dose regimen for the treatment of prosthetic joint infections: new possible options for difficult to treat infectious diseases. Infect Dis. 2021;53(6):473–475. doi:10.1080/23744235.2021.1893898
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849–1855. doi:10.1128/AAC.04550-14
   PubMed Web of Science ®Google Scholar
• Cojutti PG, Rinaldi M, Zamparini E, et al. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections. Antimicrob Agents Chemother. 2021;65(5): e02260–20. doi:10.1128/AAC.02260-20.
   PubMed Web of Science ®Google Scholar
• Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48(1):63–68. doi:10.1128/AAC.48.1.63-68.2004
   PubMed Web of Science ®Google Scholar
• FDA Approved Drug Products: CUBICIN (daptomycin) injection. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021572s063,064lbl.pdf. Accessed December 31, 2021.
   Google Scholar
• Montange D, Berthier F, Leclerc G, et al. Penetration of daptomycin into bone and synovial fluid in joint replacement. Antimicrob Agents Chemother. 2014;58(7):3991–3996. doi:10.1128/AAC.02344-14
   PubMed Web of Science ®Google Scholar
• Goutelle S, Roux S, Gagnieu MC, et al. Pharmacokinetic variability of daptomycin during prolonged therapy for bone and joint infections. Antimicrob Agents Chemother. 2016;60(5):3148–3151. doi:10.1128/AAC.02597-15
   Web of Science ®Google Scholar
• Bricca R, Goutelle S, Roux S, et al. Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection. J Antimicrob Chemother. 2019;74(4):1012–1020. doi:10.1093/jac/dky541
   Web of Science ®Google Scholar
• Garreau R, Bricca R, Gagnieu MC, et al. Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference. J Antimicrob Chemother. 2021;76(5):1250–1257. doi:10.1093/jac/dkab006
   Web of Science ®Google Scholar
• Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS Jr. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother. 2006;50(4):1222–1227. doi:10.1128/AAC.50.4.1222-1227.2006
   PubMed Web of Science ®Google Scholar
• Chambers J, Page-Sharp M, Salman S, et al. Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations. Eur J Clin Pharmacol. 2019;75(4):511–517. doi:10.1007/s00228-018-2597-z
   PubMed Web of Science ®Google Scholar
• Goutelle S, Valour F, Gagnieu MC, Laurent F, Chidiac C, Ferry T. Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection. J Antimicrob Chemother. 2018;73(4):987–994. doi:10.1093/jac/dkx477
   PubMed Web of Science ®Google Scholar
• Veganzones J, Montero A, Maseda E; Servicio de Anestesia UdCCQ, Hospital Universitario La Paz, Madrid. New evidence on the use of fosfomycin for bacteremia and infectious endocarditis. Rev Esp Quimioter. 2019;32(Suppl 1):25.
   Google Scholar
• Lepak AJ, Zhao M, VanScoy B, et al. In vivo pharmacokinetics and pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61(6). doi:10.1128/AAC.00476-17.
   Web of Science ®Google Scholar
• Docobo-Perez F, Drusano GL, Johnson A, et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother. 2015;59(9):5602–5610. doi:10.1128/AAC.00752-15
   PubMed Web of Science ®Google Scholar
• Morata L, Soriano A. The role of fosfomycin in osteoarticular infection. Rev Esp Quimioter. 2019;32(Suppl1):30–36.
   Google Scholar
• Schintler MV, Traunmuller F, Metzler J, et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother. 2009;64(3):574–578. doi:10.1093/jac/dkp230
   PubMed Web of Science ®Google Scholar
• Tsegka KG, Voulgaris GL, Kyriakidou M, Kapaskelis A, Falagas ME. Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review. Expert Rev Anti Infect Ther. 2021;1–11. doi:10.1080/14787210.2021.1932463
   Web of Science ®Google Scholar
• Rinaldi M, Cojutti PG, Zamparini E, et al. Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction. Antimicrob Agents Chemother. 2021;65(5). doi:10.1128/AAC.02038-20.
   Web of Science ®Google Scholar